Form 13-F position report

ALLOGENE THERAPEUTICS INC

Reported by Candriam S C A

ALLO CUSIP 019770106 Manager CIK 0001537014

Reported 5,422,820 shares, up 1,086,524 (25.1%) from the prior quarter.

Reported value -3.4%; share count 25.1% vs. the prior quarter.

Added
% of reported 13F value 0.04% This manager · Q3 2026
Shares 5,422,820 Quarter-end amount reported
Reported value $8,708,213 Fair value at quarter end
Consecutive quarters held 4 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2025-12-31 3158867
2026-03-31 7313456
2026-06-30 9010818
2026-09-30 8708213

Quarterly position history

How this manager's reported quarter-end position changed over time.

4 quarters
Quarterly reported position history for ALLOGENE THERAPEUTICS INC held by Candriam S C A.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 5,422,820 +1,086,524 (25.1%) 0.04% $8,708,213 2026-11-03
Q2 2026 Added 4,336,296 +1,338,978 (44.7%) 0.04% $9,010,818 2026-08-13
Q1 2026 Added 2,997,318 +691,674 (30.0%) 0.04% $7,313,456 2026-04-30
Q4 2025 New 2,305,644 +2,305,644 (0.0%) 0.02% $3,158,867 2026-02-13
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

229 managers reported ALLOGENE THERAPEUTICS INC for Q3 2026.

Managers reporting ALLOGENE THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 30,927,343 +780,380 < 0.01% $49,483,750 9 qtrs
CITADEL ADVISORS LLC Added 24,558,325 +14,470,555 < 0.01% $39,293,320 32 qtrs
PFIZER INC Unchanged 22,032,040 0 22.13% $36,352,866 8 qtrs
Frazier Life Sciences Management L P Unchanged 22,446,668 0 0.89% $35,914,669 11 qtrs
STATE STREET CORPORATION Reduced 16,326,197 -2,699,629 < 0.01% $26,121,915 32 qtrs
PRIMECAP MANAGEMENT CO CA Added 13,146,840 +23,400 0.01% $21,034,944 24 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Reduced 12,050,271 -116,365 < 0.01% $19,280,434 3 qtrs
UBS Group AG Added 10,704,296 +7,665,904 < 0.01% $17,126,874 32 qtrs
FMR LLC Reduced 10,599,559 -1,409,484 < 0.01% $16,959,295 32 qtrs
Sio Capital Management LLC Reduced 9,104,151 -4,219,280 2.76% $14,566,642 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 03, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
5,422,820
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.